Rebecca Bomar, MD
Rheumatology · Concord, NCNPI 1417241373
Payments from drug & device makers
What this record shows
This record is dominated by education: $398 of the $455 with a category attached, or 87.4%. Every reported general payment came from a single manufacturer, Johnson & Johnson. Reporting peaked in 2024 at $257 and has fallen 61.0% since, to $100 in 2025. That places this record below the midpoint for rheumatology clinicians in NC, where the typical reported total is $3,350.
Across 9 payments — averaging $50.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$455
What the payments were for
- Food & beverage$5813%
- Education$39887%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 9 | $455 |
How this compares
$455 in reported general payments places this provider in the 25th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 49 | $477,000 |
| Humira(Cf)Adalimumab | 21 | $243,519 |
| Enbrel SureclickEtanercept | 26 | $194,287 |
| KevzaraSarilumab | 40 | $169,178 |
| EnbrelEtanercept | 19 | $141,392 |
| Enbrel MiniEtanercept | 18 | $124,043 |
| RinvoqUpadacitinib | 18 | $111,748 |
| Xeljanz XrTofacitinib Citrate | 14 | $89,565 |
| Actemra ActpenTocilizumab | 18 | $87,611 |
| OtezlaApremilast | 19 | $82,573 |
| ForteoTeriparatide | 14 | $60,369 |
| ActemraTocilizumab | 15 | $52,889 |
| Hydroxychloroquine Sulfate | 395 | $11,468 |
| MethotrexateMethotrexate Sodium | 224 | $5,749 |
| Leflunomide | 99 | $4,257 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Concord
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
- Jill ZouzoulasCharlotte$377K
- Jill VargoAsheville$245K
- Robert HolmesPollocksville$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.